“Although some people may have a preference for the traditional Novavax protein-based vaccine, those who are at higher risk of catching COVID-19 should not wait for the approval of the Novavax vaccine to get their shot,” the authors write.
Prakash Nagarkatti and Mitzi Nagarkatti
Dr. Prakash Nagarkatti currently serves as vice president for research and as the Carolina Distinguished Professor of pathology, microbiology and immunology at the University of South Carolina. In his role as VPR at USC, he oversees research enterprise of approximately $280 million. He currently directs three federally-funded research centers. He has published over 300 peer-reviewed papers in the areas of inflammation. For his outstanding contributions to science, Dr. Nagarkatti was elected Fellow of American Association for the Advancement of Science, Fellow of Academy of Toxicological Sciences and a Fellow of the National Academy of Inventors. Dr. Mitzi Nagarkatti is the SmartState Endowed Chair of Center for Cancer Drug Discovery as well as the Carolina Distinguished Professor and chair of the Department of Pathology, Microbiology and Immunology at the School of Medicine at the University of South Carolina. In 2005, Dr. Nagarkatti moved from the Medical College of Virginia where she was a Professor in the Department of Microbiology and Immunology as well as directed the Immune Mechanisms Program of the National Cancer Institute designated Massey Cancer Center.
Dr. Nagarkatti’s research is broad-based and encompasses Inflammation, Autoimmunity, Complementary and Alternative Medicine, Cancer Immunology and Immunotherapy, and Immunotoxicology.